SEGMENT REPORTING (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle

The following table reconciles reported revenues to net (loss) income under the significant expense principle for the years ended December 31, 2024 and 2023:

		December 31,		December 31,
		2024		2023
(in millions)
Revenues:
Product revenue, net		76.5		-
Royalties		0.5		0.2
Total revenues	$	77.0	$	0.2
Operating expenses:
Cost of goods sold		1.3		-
Research and development
Research and clinical expenses		67.9		74.9
Chemistry, manufacturing, and control expenses		26.2		$42.5
Selling, general and administrative
Commercial expenses		72.0		27.4
Other segment expenses*		83.3		49.4
Total operating expenses	$	250.7	$	194.2
Loss from operations		(173.7)		(193.9)
Total interest and other income (expense)		(0.9)		9.8
Net loss	$	(174.6)	$	(184.1)

*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.